川北医学院学报2016，Vol.31Issue(5)：752-755,4.DOI:10.3969/j.issn.1005-3697.2016.05.037
西妥昔单抗联合化疗治疗结直肠癌的疗效分析
Analysis of efficacy of first-line treatment with cetuximab combined with chemotherapy in treatment of K-Ras mild-type metastatic colorectal canc-er
帕提玛·阿布力米提 1罗玲娟 1谢新梅 1张洪亮1
作者信息
- 1. 新疆医科大学附属中医医院肿瘤二科，新疆 乌鲁木齐 830000
- 折叠
摘要
Abstract
Objective:To explore the efficacy and safety of first-line treatment with cetuximab combined with different chemo-therapy in the treatment of K-Ras mild-type metastatic colorectal cancer (mCRC).Methods:A total of 58 patients with K-Ras mild-type mCRC were randomly divided into observation group and control group,29 cases for each group.Control group was treated with sin-gle chemotherapy while observation group with cetuximab combined with chemotherapeutic protocol.Both groups finished the 8-cycle treatment.Objective response rate (ORR)and disease control rate (DCR)were compared between two groups,median progression-free survival time (PFS)and median overall survival (OS)were compared in both groups,and the rate of rash was compared.Results:There was no significant difference between two groups in ORR (P >0.05 ),but observation group was markedly higher in DCR than control group (P <0.05).Meanwhile,observation group was notably loner in median PFS and median OS (P <0.05),and prominent-ly higher in the rate of rash than control group (P <0.05).Conclusion:First-line treatment with cetuximab combined with chemothera-peutic protocol can significantly increase the short-term efficacy,and prolong the median PFS and OS of patients with K-Ras mild-type mCRC,and the adverse reactions mainly focus on rash.关键词
西妥昔单抗/K-Ras基因/结直肠癌/化疗Key words
Cetuximab/K-Ras gene/Colorectal cancer/Chemotherapy分类
医药卫生引用本文复制引用
帕提玛·阿布力米提,罗玲娟,谢新梅,张洪亮..西妥昔单抗联合化疗治疗结直肠癌的疗效分析[J].川北医学院学报,2016,31(5):752-755,4.
